Michael Zinda
Impact in
- Oncology top 5%
- Cytokine Signaling Pathways and Interactions
- PARP inhibition in cancer therapy
- Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
Papers in
-
- Protein Degradation and Inhibitors 6
- PI3K/AKT/mTOR signaling in cancer 6
- CRISPR and Genetic Engineering 3
- Oncology 18
- Cytokine Signaling Pathways and Interactions 13
- PARP inhibition in cancer therapy 3
- Co-authors
- Charles K. Singleton (2 shared papers)Chris J. Vlahos (1 shared paper)Dennis Huszar (8 shared papers)Stephen E. Fawell (8 shared papers)Ping Yang (1 shared paper)Michal Zimmermann (4 shared papers)Corinne Reimer (6 shared papers)Jeremy Setton (1 shared paper)
- Journals
- Bioorganic & Medicinal Chemistry Letters (7 papers)Cancer Research (5 papers)Molecular Cancer Therapeutics (4 papers)Oncotarget (4 papers)Clinical Cancer Research (2 papers)
- Partner nations
- United StatesUnited KingdomJapan
In The Last Decade
Michael Zinda
36 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 85
- Oncology 469
- Molecular Biology 935
- Genetics 135
- Cancer Research 188
- Hematology 113
Countries citing papers authored by Michael Zinda
This map shows the geographic impact of Michael Zinda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Zinda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Zinda more than expected).
Fields of papers citing papers by Michael Zinda
This network shows the impact of papers produced by Michael Zinda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Zinda. The network helps show where Michael Zinda may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Zinda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 143 | |
| 2 | AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. | 2001 | 132 |
| 3 | 2021 | 116 | |
| 4 | 2011 | 93 | |
| 5 | 2008 | 77 | |
| 6 | 1998 | 74 | |
| 7 | 2001 | 69 | |
| 8 | 2018 | 67 | |
| 9 | 2015 | 57 | |
| 10 | 2015 | 54 | |
| 11 | 2014 | 53 | |
| 12 | 2013 | 52 | |
| 13 | 1998 | 49 | |
| 14 | 2013 | 48 | |
| 15 | 2018 | 41 | |
| 16 | 2012 | 38 | |
| 17 | 2014 | 35 | |
| 18 | 2022 | 34 | |
| 19 | 2008 | 30 | |
| 20 | 2016 | 27 |
About Michael Zinda
Michael Zinda is a scholar working on Molecular Biology, Oncology, Genetics, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 37 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Protein Degradation and Inhibitors (6 papers), Cancer Mechanisms and Therapy (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Chronic Myeloid Leukemia Treatments (4 papers), PARP inhibition in cancer therapy (3 papers) and CRISPR and Genetic Engineering (3 papers). The work is most often cited by research in Oncology (469 citations), Molecular Biology (935 citations), Genetics (135 citations), Cancer Research (188 citations) and Hematology (113 citations). Michael Zinda has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Charles K. Singleton, Chris J. Vlahos, Dennis Huszar, Stephen E. Fawell, Ping Yang, Michal Zimmermann, Corinne Reimer, Jeremy Setton, Celina M. D’Cruz and Stephanos Ioannidis. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Cancer Research, Molecular Cancer Therapeutics, Oncotarget and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.